Literature DB >> 18464767

IL-1 trap go-ahead.

Mark Ratner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18464767     DOI： 10.1038/nbt0508-485b

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

1.  Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.

Authors:  Leigh D Church; Michael F McDermott
Journal:  Nat Clin Pract Rheumatol       Date:  2008-11-18

2.  Treatment and management of pseudogout: insights for the clinician.

Authors:  Paul Macmullan; Geraldine McCarthy
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 3.  Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.

Authors:  Manfred Kunz; Saleh M Ibrahim
Journal:  Mediators Inflamm       Date:  2009-10-26       Impact factor: 4.711

Review 4.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

Review 5.  The NLRP3 Inflammasome and Its Role in the Pathogenicity of Leukemia.

Authors:  Laura Urwanisch; Michela Luciano; Jutta Horejs-Hoeck
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 5.923

6.  Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).

Authors:  Leigh D Church; Sinisa Savic; Michael F McDermott
Journal:  Biologics       Date:  2008-12

7.  Blood soluble interleukin 1 receptor accessory protein levels are consistently low throughout the menstrual cycle of women with endometriosis.

Authors:  Nadège Michaud; Mahera Al-Akoum; Ali Akoum
Journal:  Reprod Biol Endocrinol       Date:  2014-06-16       Impact factor: 5.211

8.  Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases.

Authors:  Congfei Xu; Zidong Lu; Yingli Luo; Yang Liu; Zhiting Cao; Song Shen; Hongjun Li; Jing Liu; Kaige Chen; Zhiyao Chen; Xianzhu Yang; Zhen Gu; Jun Wang
Journal:  Nat Commun       Date:  2018-10-05       Impact factor: 14.919
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.